<DOC>
	<DOCNO>NCT00112034</DOCNO>
	<brief_summary>The purpose study determine efficacy safety combination therapy AVONEX plus low dose oral methotrexate ( MTX ) , every month course intravenous methylprednisolone ( IVMP ) , patient continue disease activity AVONEX monotherapy .</brief_summary>
	<brief_title>AVONEX速 Combination Trial - `` ACT ''</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age 18 55 , inclusive Diagnosis MS A relapsingremitting course Expanded Disability Status Scale ( EDSS ) score 0.05.5 inclusive Baseline Currently receive AVONEX速 therapy Treated AVONEX速 least 6 consecutive month prior Breakthrough disease ( clinical relapse gadoliniumenhancing MRI lesion ) prior 12 month , least 6 month initiate AVONEX therapy . History cirrhosis , chronic hepatitis , currently active hepatitis History poorlycontrolled hypertension , diabetes mellitus , peptic ulcer disease History aseptic bone necrosis , osteoporosis , osteoporosisrelated bone fracture History steroidinduced psychosis . History abnormal laboratory result indicate significant illness History severe allergic anaphylactic reaction know drug hypersensitivity intolerance MTX , IVMP , AVONEX速 . History allergy albumin History episode suicidal ideation severe depression within 3 month Screening Visit . History seizure within 3 month prior Screening Visit . Diagnosis primary progressive , secondary progressive , progressive relapse MS MS relapse onset within 60 day prior Baseline Visit Any metallic electronic material device body , condition precludes subject undergoing MRI gadolinium administration A clinically significant infectious illness ( e.g. , cellulitis , abscess , pneumonia , septicemia ) within 30 day Screening Visit Abnormal blood test , perform Screening Visit , exceed limit define study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing-Remitting</keyword>
	<keyword>AVONEX</keyword>
	<keyword>Combination</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>IV Methylprednisolone</keyword>
	<keyword>IVMP</keyword>
	<keyword>ACT</keyword>
	<keyword>MTX</keyword>
</DOC>